Nab-paclitaxel plus gemcitabine for unresectable pancreatic cancer: A pooled meta-analysis

被引：0
|
作者：
Zhang, Y. [1 ]
Shi, S. [1 ]
Yu, X. [1 ]
机构：
[1] Fudan Univ, Shanghai Canc Ctr, Dept Pancreat Surg, Shanghai, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2018年 / 29卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
728P
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Conversion Surgery for Unresectable Pancreatic Cancer Treated With FOLFIRINOX or Gemcitabine Plus Nab-paclitaxel
    Ide, Yasushi
    Otsuka, Taiga
    Shimokawa, Mototsugu
    Koga, Futa
    Ueda, Yujiro
    Nakazawa, Junichi
    Komori, Azusa
    Otsu, Satoshi
    Arima, Shiho
    Fukahori, Masaru
    Makiyama, Akitaka
    Shinohara, Yudai
    Ueno, Shohei
    Taguchi, Hiroki
    Honda, Takuya
    Shibuki, Taro
    Nio, Kenta
    Ureshino, Norio
    Mizuta, Toshihiko
    Mitsugi, Kenji
    Shirakawa, Tsuyoshi
    ANTICANCER RESEARCH, 2023, 43 (04) : 1817 - 1826
  • [2] Meta-analysis of gemcitabine plus nab-paclitaxel combined with targeted agents in the treatment of metastatic pancreatic cancer
    Li, Zhong-Hui
    Ma, Yin-Jie
    Jia, Zong-Hang
    Weng, Yue-Yan
    Zhang, Ping
    Zhu, Shi-Jie
    Wang, Fang
    WORLD JOURNAL OF CLINICAL CASES, 2022, 10 (27) : 9703 - 9713
  • [3] Meta-analysis of gemcitabine plus nab-paclitaxel combined with targeted agents in the treatment of metastatic pancreatic cancer
    Zhong-Hui Li
    Yin-Jie Ma
    Zong-Hang Jia
    Yue-Yan Weng
    Ping Zhang
    Shi-Jie Zhu
    Fang Wang
    World Journal of Clinical Cases, 2022, 10 (27) : 9703 - 9713
  • [4] The retrospective analysis of gemcitabine plus nab-paclitaxel in advanced pancreatic cancer
    Ueno, M.
    Kobayashi, S.
    Ohkawa, S.
    Tezuka, S.
    Moriya, S.
    Morimoto, M.
    ANNALS OF ONCOLOGY, 2015, 26 : 67 - 67
  • [5] Comparative effectiveness of gemcitabine vs gemcitabine plus nab-paclitaxel vs FOLFIRINOX for unresectable pancreatic cancer
    Yamamoto, Shun
    Ueno, Hideki
    Tanaka, Midori
    Inagaki, Yuji
    Ohba, Akihiro
    Sakamoto, Yasunari
    Kondo, Shunsuke
    Morizane, Chigusa
    Okusaka, Takuji
    ANNALS OF ONCOLOGY, 2017, 28
  • [6] Pharmacoethnicity of FOLFIRINOX versus gemcitabine plus nab-paclitaxel in metastatic pancreatic cancer: a systematic review and meta-analysis
    Lee, Yoon Suk
    Lee, Jong-chan
    Kim, Jae-Hyeong
    Kim, Jaihwan
    Hwang, Jin-Hyeok
    SCIENTIFIC REPORTS, 2021, 11 (01)
  • [7] Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
    Von Hoff, Daniel D.
    Ervin, Thomas
    Arena, Francis P.
    Chiorean, E. Gabriela
    Infante, Jeffrey
    Moore, Malcolm
    Seay, Thomas
    Tjulandin, Sergei A.
    Ma, Wen Wee
    Saleh, Mansoor N.
    Harris, Marion
    Reni, Michele
    Dowden, Scot
    Laheru, Daniel
    Bahary, Nathan
    Ramanathan, Ramesh K.
    Tabernero, Josep
    Hidalgo, Manuel
    Goldstein, David
    Van Cutsem, Eric
    Wei, Xinyu
    Iglesias, Jose
    Renschler, Markus F.
    NEW ENGLAND JOURNAL OF MEDICINE, 2013, 369 (18): : 1691 - 1703
  • [8] Pharmacoethnicity of FOLFIRINOX versus gemcitabine plus nab-paclitaxel in metastatic pancreatic cancer: a systematic review and meta-analysis
    Yoon Suk Lee
    Jong-chan Lee
    Jae-Hyeong Kim
    Jaihwan Kim
    Jin-Hyeok Hwang
    Scientific Reports, 11
  • [9] Nab-paclitaxel plus gemcitabine as first-line treatment for advanced pancreatic cancer: a systematic review and meta-analysis
    Zhang, Yiyin
    Xu, Jin
    Hua, Jie
    Liu, Jiang
    Liang, Chen
    Meng, Qingai
    Ni, Quanxing
    Shi, Si
    Yu, Xianjun
    JOURNAL OF CANCER, 2019, 10 (18): : 4420 - 4429
  • [10] Impact of Statin Use on Survival in Patients With Unresectable Pancreatic cancer Receiving Gemcitabine Plus Nab-Paclitaxel
    Saito, Kei
    Nakai, Yousuke
    Sasaki, Takashi
    Takeda, Tsuyoshi
    Ueno, Makoto
    Tezuka, Shun
    Isayama, Hiroyuki
    Tomishima, Ko
    Kojima, Yasushi
    Yamamoto, Natsuyo
    Ito, Yukiko
    Oyama, Hiroki
    Toda, Nobuo
    Takagi, Kaoru
    Matsubara, Saburo
    Mohri, Dai
    Sato, Tatsuya
    Fujishiro, Mitsuhiro
    PANCREAS, 2025, 54 (02) : e107 - e113
12345